PTC Therapeutics (PTCT) Tops Q2 EPS by 23c, provides guidance

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.83), $0.23 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $178.9 million versus the consensus estimate of $171.74 million.

GUIDANCE:

PTC Therapeutics sees FY2025 revenue of $650-800 million, versus the consensus of $1746 million.

PTC anticipates full-year 2025 GAAP R&D and SG&A expense to be between $805 and $835 million.
PTC anticipates full-year 2025 non-GAAP R&D and SG&A expense to be between $730 and $760 million, excluding estimated non-cash, stock-based compensation expense of $75 million

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• Obsidian Energy Increases Syndicated Credit Facility